Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note

Graham, Jacqueline M.; Sussman, Jon D.; Ford, Kay S.; Sagar, Harvey J.; Graham, J M; Sussman, J D; Ford, K S; Sagar, H J
November 1998
Journal of Neurology, Neurosurgery & Psychiatry;Nov1998, Vol. 65 Issue 5, p774
Academic Journal
journal article
No abstract available.


Related Articles

  • Antipsychotics.  // Reactions Weekly;4/11/2009, Issue 1247/1248, p6 

    The article describes the case of a 74-year-old woman who developed tardive parkinsonism after being treated with chlorpromazine, tiotixine, perphenazine, haloperidol and olanzapine for bipolar disorder. The woman died from complications associated with a prolonged hospitalisation after a manic...

  • When a Parkinson's disease patient starts to hallucinate. Poewe, Werner // Practical Neurology (BMJ Publishing Group);Aug2008, Vol. 8 Issue 4, p238 

    The article presents an analysis regarding the emergence of visual hallucinations occurring in patients with Parkinson's disease. It states that though age and cognitive decline are important intrinsic factors, comorbid conditions such as infection and dehydration triggers hallucinosis. It...

  • Add'l Mirapex ER approval.  // MPR - Residents' Edition;Spring/Summer2010, Vol. 19 Issue 1, pA10 

    The article reports on the approval for Mirapex ER's advanced idiopathic Parkinson's disease's expanded indication treatment.

  • Improving therapy adherence in Parkinson's disease.  // British Journal of Hospital Medicine (17508460);Nov2009, Vol. 70 Issue 11, p617 

    The article reports on the launch of pramipexole (Mirapexin) by the Boehringer-Ingelheim GmbH for the palliative treatment of idiopathic Parkinson's disease in Great Britain. It is noted that the drug can be a combination therapy with levodopa, a dopaminergic, for improved therapeutic effects....

  • FDA approvals. Elliott, William T. // Critical Care Alert;Jul2007 Pharmacology Watch, p2 

    The article reports on the approvals of three drugs by the U.S. Food and Drug Administration, including a transdermal patch for the treatment of early stage idiopathic Parkinson's disease.

  • Erratum.  // Drugs;2012, Vol. 72 Issue 6, p870 

    A correction to the article "Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson's Disease," by S. M. Hoy and G. M. Keating that was published in 2012 is presented.

  • Mirapex ok'd as Parkinson's disease treatment.  // Drug Store News;10/20/97, Vol. 19 Issue 17, pCP6 

    Reports that the pramipexole formulation of Pharmacia & Upjohn and Boehringer Ingelheim has been approved for symptomatic treatment of idiopathic Parkinson's disease in the United States.

  • Olanzapine: a proarrhythmic drug? Gupta, Nitin; Malhotra, Pankaj // Canadian Journal of Psychiatry;Sep2002, Vol. 47 Issue 7, p683 

    Presents cases illustrating the effects of olanzapine in the treatment of patient with parkinsonism. Association of noncardiac drugs with QT interval prolongation; Theory on the leading of olanzapine to QT interval prolongation; Pharmacokinetic profile of olanzapine.

  • Physiology and treatment of Parkinson's disease. Thornton, Phillip L.; Helms, Kristen // Drug Topics;4/19/2004, Vol. 148 Issue 8, p64 

    Focuses on the physiology and treatment of Parkinson's disease. Overview of Parkinson's disease; Symptoms of Parkinson's disease; Identification of the mutations of several different genes resulting in decreased degradation of the proteins α-synuclein, ubiquitin and parkin; Hypothesis on...

  • Comparison of two forms of intensive speech treatment for Parkinson disease. Ramig, Lorraine Olson; Countryman, Stefanie // Journal of Speech & Hearing Research;Dec95, Vol. 38 Issue 6, p1232 

    Investigates the effect of two forms of intensive speech treatment, respiratory (R) and voice and respiration (LSVT), on the voice and speech deficits associated with Idiopathic Parkinson disease. Indications that LSVT treatment is more effective than R treatment alone for improving vocal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics